Louise M. Collins
Luimneach, M, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Cardiopulmonary Exercise Testing in Adults with Cystic Fibrosis: A Retrospective Study.
Journal: Annals of the American Thoracic Society
Published: August 07, 2025
Alpha-synuclein-induced upregulation of SKI family transcriptional corepressor 1: A new player in aging and Parkinson's disease?
Journal: Neural regeneration research
Published: September 27, 2024
The class-IIa HDAC inhibitor TMP269 promotes BMP-Smad signalling and is neuroprotective in in vitro and in vivo 6-hydroxydopamine models of Parkinson's disease.
Journal: Neuropharmacology
Published: September 13, 2024
Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: January 31, 2023
A combined proteomics and bioinformatics analysis of ZNHIT1-interacting proteins reveals a significant enrichment in proteins associated with mitochondrial function.
Journal: Journal of chemical neuroanatomy
Published: December 14, 2022
Steps Ahead: Optimising physical activity in adults with cystic fibrosis: A pilot randomised trial using wearable technology, goal setting and text message feedback.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 22, 2022
Physical Activity and Sedentary Behavior in Adults With Cystic Fibrosis: Association With Aerobic Capacity, Lung Function, Sleep, Well-Being, and Quality of Life.
Journal: Respiratory care
Published: November 24, 2021
Gene Co-expression Analysis of the Human Substantia Nigra Identifies ZNHIT1 as an SNCA Co-expressed Gene that Protects Against α-Synuclein-Induced Impairments in Neurite Growth and Mitochondrial Dysfunction in SH-SY5Y Cells.
Journal: Molecular neurobiology
Published: November 23, 2021
Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
Journal: Brain, behavior, and immunity
Published: November 11, 2021
Accuracy of the ActivPAL and Fitbit Charge 2 in measuring step count in Cystic Fibrosis.
Journal: Physiotherapy theory and practice
Published: August 09, 2021
Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Journal: Neural regeneration research
Published: June 08, 2021
Last Updated: 09/26/2026